{"news_desk": "Business", "print_page": "1", "section_name": "Business Day", "subsection_name": "DealBook", "byline": {"contributor": "Liz Moyer, Chad Bray and Alan Rappeport contributed reporting.", "original": "By MICHAEL J. de la MERCED, DAVID GELLES and LESLIE PICKER", "person": [{"middlename": "J.", "firstname": "Michael", "lastname": "de la MERCED", "rank": 1, "role": "reported", "organization": ""}, {"rank": 2, "role": "reported", "firstname": "David", "organization": "", "lastname": "GELLES"}, {"rank": 3, "role": "reported", "firstname": "Leslie", "organization": "", "lastname": "PICKER"}]}, "abstract": "Pfizer's $152 billion merger with Allergan, maker of Botox based in Dublin, revives strong debate over whether mergers that let American company relocate to lower-tax country are good idea; Pfizer chief executive Ian C Read says it is good deal that will create more jobs; deal is expected to gain approval.", "type_of_material": "News", "word_count": "1485", "lead_paragraph": "The agreement would be the latest, and largest, aimed at helping an American company lower its taxes by reincorporating overseas, a tactic known as corporate inversion.", "pub_date": "2015-11-24T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "Pfizer Chief Defends Merger With Allergan as Good for U.S.", "print_headline": "Chief of Pfizer Defends Merger as Good for U.S."}, "snippet": "The agreement would be the latest, and largest, aimed at helping an American company lower its taxes by reincorporating overseas, a tactic known as corporate inversion.", "multimedia": [{"height": 126, "url": "images/2015/11/24/business/24-pfizer-web1/24-pfizer-web1-thumbWide.jpg", "legacy": {"widewidth": "190", "wideheight": "126", "wide": "images/2015/11/24/business/24-pfizer-web1/24-pfizer-web1-thumbWide.jpg"}, "type": "image", "width": 190, "subtype": "wide"}, {"height": 332, "url": "images/2015/11/24/business/24-pfizer-web1/24-pfizer-web1-articleLarge.jpg", "legacy": {"xlargewidth": "600", "xlargeheight": "332", "xlarge": "images/2015/11/24/business/24-pfizer-web1/24-pfizer-web1-articleLarge.jpg"}, "type": "image", "width": 600, "subtype": "xlarge"}, {"height": 75, "url": "images/2015/11/24/business/24-pfizer-web1/24-pfizer-web1-thumbStandard-v3.jpg", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2015/11/24/business/24-pfizer-web1/24-pfizer-web1-thumbStandard-v3.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "subtype": "thumbnail"}], "web_url": "http://www.nytimes.com/2015/11/24/business/dealbook/pfizer-allergan-merger-inversion.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Allergan Inc", "name": "organizations"}, {"rank": "11", "is_major": "N", "value": "Dublin (Ireland)", "name": "glocations"}, {"rank": "12", "is_major": "N", "value": "Mergers, Acquisitions and Divestitures", "name": "subject"}, {"rank": "2", "is_major": "Y", "value": "Pfizer Inc", "name": "organizations"}, {"rank": "3", "is_major": "Y", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "4", "is_major": "Y", "value": "Corporate Taxes", "name": "subject"}, {"rank": "5", "is_major": "Y", "value": "Tax Shelters", "name": "subject"}, {"rank": "6", "is_major": "Y", "value": "Ireland", "name": "glocations"}, {"rank": "7", "is_major": "Y", "value": "Read, Ian C", "name": "persons"}, {"rank": "8", "is_major": "N", "value": "Relocation of Business", "name": "subject"}, {"rank": "9", "is_major": "N", "value": "Botox (Drug)", "name": "subject"}, {"rank": "10", "is_major": "N", "value": "AstraZeneca PLC", "name": "organizations"}], "blog": [], "_id": "5653069438f0d83c3238dbd6", "source": "The New York Times"}